FDA Approves Tibsovo for Acute Myeloid Leukemia

Share this content:
FDA Approves Tibsovo for Acute Myeloid Leukemia
FDA Approves Tibsovo for Acute Myeloid Leukemia

MONDAY, July 23, 2018 (HealthDay News) -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene.

Tibsovo's effectiveness was clinically studied among 174 adults with AML who had the defective IDH1 gene. The most common side effects of the drug included fatigue, increase in white blood cells, joint pain, diarrhea, shortness of breath, swelling of the arms and legs, and mouth sores.

Because it could harm a newborn baby, women who are breastfeeding shouldn't take Tibsovo, the FDA said. The drug's label includes the agency's most serious boxed warning about the adverse reaction known as differentiation syndrome, characterized by possible symptoms such as fever, dyspnea, radiographic pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain, peripheral edema, and multi-organ dysfunction. Other possible serious side effects include QT prolongation and Guillain-Barré syndrome, the agency said.

"The use of Tibsovo is associated with a complete remission in some patients and a reduction in the need for both red cell and platelet transfusions," Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence, said in a statement.

Tibsovo is produced by Massachusetts-based Agios Pharmaceuticals. The FDA said it simultaneously approved a new diagnostic to detect cases of AML caused by the defective gene. The new test is produced by Abbott Laboratories.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Customizable Insulin Pump

FDA Approves First Customizable Insulin Pump

Product works by delivering insulin under the skin at set or variable rates

Sepsis Common in Terminal Hospitalizations, Discharges

Sepsis Common in Terminal Hospitalizations, Discharges

Most common underlying causes of death in sepsis are solid and hematologic cancers, chronic heart disease

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer older men than women, even with higher risk, undergo DXA screening, 25(OH)D measurement

is free, fast, and customized just for you!




Already a member?

Sign In Now »